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DOI 10.1186/s40168-015-0071-zRESEARCH Open AccessMaternal fucosyltransferase 2 status affects the
gut bifidobacterial communities of breastfed
infants
Zachery T Lewis1,4, Sarah M Totten2,4, Jennifer T Smilowitz1,4, Mina Popovic5, Evan Parker2, Danielle G Lemay6,
Maxwell L Van Tassell7, Michael J Miller7, Yong-Su Jin7, J Bruce German1,4, Carlito B Lebrilla2,4 and David A Mills1,3,4*Abstract
Background: Individuals with inactive alleles of the fucosyltransferase 2 gene (FUT2; termed the ‘secretor’ gene)
are common in many populations. Some members of the genus Bifidobacterium, common infant gut commensals,
are known to consume 2′-fucosylated glycans found in the breast milk of secretor mothers. We investigated the
effects of maternal secretor status on the developing infant microbiota with a special emphasis on bifidobacterial
species abundance.
Results: On average, bifidobacteria were established earlier and more often in infants fed by secretor mothers
than in infants fed by non-secretor mothers. In secretor-fed infants, the relative abundance of the Bifidobacterium
longum group was most strongly correlated with high percentages of the order Bifidobacteriales. Conversely, in
non-secretor-fed infants, Bifidobacterium breve was positively correlated with Bifidobacteriales, while the B. longum
group was negatively correlated. A higher percentage of bifidobacteria isolated from secretor-fed infants consumed
2′-fucosyllactose. Infant feces with high levels of bifidobacteria had lower milk oligosaccharide levels in the feces
and higher amounts of lactate. Furthermore, feces containing different bifidobacterial species possessed differing
amounts of oligosaccharides, suggesting differential consumption in situ.
Conclusions: Infants fed by non-secretor mothers are delayed in the establishment of a bifidobacteria-laden
microbiota. This delay may be due to difficulties in the infant acquiring a species of bifidobacteria able to consume
the specific milk oligosaccharides delivered by the mother. This work provides mechanistic insight into how milk
glycans enrich specific beneficial bacterial populations in infants and reveals clues for enhancing enrichment of
bifidobacterial populations in at risk populations - such as premature infants.
Keywords: Bifidobacteria, Secretor, Infant, Breastfeeding, FUT2, Marker gene sequencing, Human milk
oligosaccharides, Short-chain fatty acidsBackground
The establishment of the intestinal microbiota after birth
is an important event in the life of a newborn [1]. Bifido-
bacterium species are among the early colonizers of
breastfed infants [2], with evidence that they are uniquely
beneficial to the newborn infant in various ways [3-7].
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unless otherwise stated.milk oligosaccharides (HMOs) are protective to infants [8]
and function as a prebiotic in the establishment of bifido-
bacteria. Select members of the genus Bifidobacterium
commonly found in breastfed infants are able to utilize
HMOs as carbon sources, including fucosylated oligo-
saccharides [9-13]. The relationship between mothers,
infants, and bifidobacterial species appears to have co-
evolved over mammalian history [14], perhaps to aid the
infant in avoiding infection. Bifidobacteria have also
been shown to reduce inflammation and gut permeabil-
ity [7,15-17]. A recent analysis of breastfed infants in
Bangladesh revealed that higher bifidobacterial populationshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teral vaccines early in infancy [5]. Bifidobacteria are not
alone in their ability to consume HMOs, as members of the
genus Bacteroides are known to consume some types of
HMOs [18]. These two groups are both involved in the
production of short-chain fatty acids and lactate, which
alter the pH of the environment, modulate the microbiota,
and have other systemic properties [19].
HMOs can be bound to other compounds in milk as
glycoconjugates, which may play a similar role to free
HMOs [20]. Together, free HMOs and their related gly-
coconjugates have been referred to as human milk
glycans (HMGs) [6]. Among the genes that build HMGs
in the mammary gland is the fucosyltransferase 2
(FUT2) gene, which catalyzes the transfer of fucose resi-
dues by an α1,2-linkage to glycans found in human milk.
Known as the ‘secretor’ gene because of its role in the
expression of ABO blood types in various secreted body
fluids (tears, saliva, breast milk, and so on), this gene has
well-known mutations that inactivate transferase activity
which occur in most populations across the world, in-
cluding in about 20% of the population of the United
States [21]. FUT2 seems to be under balancing selection
[22,23], as there are both advantages and disadvantages
to possessing an active copy of the gene. For example,
non-secretors are resistant to rotavirus [24], norovirus
[25], and Helicobacter pylori [26] infections, while secre-
tors have lower risk in developing type 1 diabetes [27]
and Crohn’s disease [28]. Breastfeeding mothers who are
secretors also confer resistance to diarrheal disease on
their children [29]. Morrow et al. found that there were
differences in survival between premature infants of dif-
fering secretor statuses [30], although how much the
mother’s genotype plays into this outcome is unknown.
The amount of fucosylation in breast milk is also known
to change over the course of lactation [31], which may
affect the protection conferred to an infant over time.
There are phenotypic differences in the milk glycans
from secretors and non-secretors [32] and in their
ability to deflect pathogen binding to the epithelium
[33]. HMOs containing α1,2-fucosyl linkages have been
shown to promote the growth of bifidobacteria due to
prebiotic action [34]. Bifidobacterium longum subsp.
infantis and Bifidobacterium bifidum possess glycosyl
hydrolase family 95 (GH95) fucosidases that act on
2′-fucosylated HMOs [12,35]. In other bifidobacteria
such as Bifidobacterium breve, GH29 fucosidases enable
the consumption of 2′-fucosylated HMOs [36]. Regard-
less, there is little known about how actual breast milk
from mothers of different secretor statuses affects the
resulting gut community of a breastfed infant. This
study examines the differences in infant gut microbial
populations that arise from these compositional differ-
ences in HMGs.Results
Maternal secretor status
A subset of 44 infant/mother dyads from the existing
UC Davis Foods For Health Institute Lactation Study
were selected for an analysis of the effects of a mother’s
secretor status on her infant’s gut microbiota over four
time points ranging from 7 to 120 days of life. To deter-
mine each mother’s secretor status, several specific
2′-fucosylated HMO ‘markers’ were quantitated in the
earliest milk available from each mother (Additional
file 1: Table S1). Of the 107 milk samples, 35 were found
to be from 12 non-secretor donors (33%) and 72 were
from 32 secretor donors (67%). Aside from the levels of
secretor status marker oligosaccharides, milk determined
to be from non-secretor mothers showed other signifi-
cant differences in glycan composition when compared
to secretor milk over all four time points (Table 1). Al-
though the total oligosaccharide abundance and the rela-
tive amount of total (including 2′ and 3′) fucosylation
were comparable among averaged data from the two
phenotypes, the relative abundances of non-fucosylated
neutral and sialylated structures differed. In non-secretors,
the average amount of sialylation was 23.4% ± 5.7%,
which is significantly higher than the amounts of sialyla-
tion found in secretors, which averaged 18.2% ± 4.8%
(p < 0.0001). Conversely, non-secretor milk had lower
relative amounts of non-fucosylated neutral structures
than secretor milk, with 21.3% ± 8.8% and 25.4% ± 7.3%,
respectively (p = 0.023).
To rule out some potential external factors that could
confound a microbiota comparison between the two se-
cretor phenotypes, maternal and infant demographics
and clinical characteristics were compared between the
two groups. No obvious differences between secretor
and non-secretor groups were found (Tables 2 and 3).
All infants consumed breast milk throughout the study
duration; however, based on parental reports, some in-
fants occasionally consumed limited amounts of supple-
mental infant formula and/or solid foods (see Additional
file 2: Table S2 for details). Additional file 2: Table S2
also indicates from which infants samples were available
for each of the four time points.
To validate the phenotypic designation (secretor or
non-secretor) assigned to each mother, genotypic informa-
tion about secretor status was also generated for each
mother. Mothers determined to be homozygote non-
secretors by genotype were, in all cases, also determined
to be non-secretors in phenotype as described above. In
two cases (mothers 1036 and 1041), the genotypic data
showed either homozygote secretor or heterozygote (re-
spectively), but the phenotype indicated non-secretor. In
all other cases, the homozygotic and heterozygotic secre-
tors were determined to have a secretor phenotype. In the
two aberrant cases, later time points revealed secretor
Table 1 Secretor phenotype characteristics
Measurement Non-secretor Secretor 2-tailed t-test p value
Sample size (N) 35 72 N/A
Total HMO signal (ion counts ± SD) 5.11e08 ± 1.52e08 5.61e08 ± 1.46e08 0.112
Fucosylation (ion counts ± SD) 3.55e08 ± 1.14e08 3.67e08 ± 9.50e07 0.569
% fucosylation 68.3 ± 7.8 65.8 ± 7.5 0.119
Sialylation (ion counts ± SD) 1.25e08 ± 5.19e07 1.04e08 ± 4.28e07 0.044
% sialylation 23.4 ± 5.7 18.2 ± 4.8 <0.0001
Non-fucosylated neutral (ion counts ± SD) 1.02e08 ± 4.17e07 1.44e08 ± 5.52e07 <0.0001
% non-fucosylated neutral 21.3 ± 8.8 25.4 ± 7.3 0.012
Means, standard deviations, and t-test values of each HMO (human milk oligosaccharide) class by secretor phenotype.
Table 2 Reported maternal demographics and
characteristics
Maternal characteristic Secretor (n = 32) Non-secretor (n = 12)
Maternal education
High school 1 0
Bachelor’s degree 11 1
Master’s degree 12 7
PhD or equivalent 8 4
Maternal ethnicity
Caucasian 29 10
Asian 1 1
Hispanic 2 1
Secretor genotypea
SS 6 0
Ss 25 0
ss 0 12
Maternal blood type (ABO)
Type O 15 6
Type A 15 5
Type B 1 1
Type AB 1 0
Maternal Rh factor
Positive 29 9
Negative 3 3
Parity
Primiparous 24 8
Multiparous 8 4
Birth mode
Vaginal 28 11
C-section 4 1
Infant gender
Female 17 7
Male 15 5
Values are frequencies per total sample size, n = 44. aGenotyping data missing
for one subject phenotypically described as a secretor.
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that secretor phenotype might change over the course of
lactation in some mothers.
Fecal bifidobacterial levels
To investigate if the grouping by mother’s secretor status
produced differences in the gut microbiota of the infant,
we used 16S rRNA gene amplicon sequencing to probe
the fecal microbiota of the infants. In general, the most
common bacterial groups found in all the infants were
Bifidobacteriales, Lactobacillales (mostly Streptococcus),
Bacteroides, Enterobacteriaceae, and Clostridiaceae. As
shown in Figure 1, there is a general trend towards increas-
ing amounts of Bacteroidales and Bifidobacteriales and de-
creasing amounts of Lactobacillales (mostly Streptococcus)
and Enterobacteriales over time. Differences were seen be-
tween the five C-section-born infants and the 39 vaginally
born infants, with C-section infants having much lower
levels of bifidobacteria and Bacteroides, although the num-
ber of C-section infants was too low to draw any robust
conclusions (Additional file 3: Figure S1).
When grouped by the mothers’ secretor status, differ-
ences were seen in the aggregated infants’ gut microbiota
(Figure 2). Specifically, secretor-fed infants generally had
higher relative amounts of Bifidobacterium (p < 0.05)
and Bacteroides and lower levels of enterobacteria, clos-
tridia, and streptococci (p < 0.05). To verify the higher
levels of bifidobacteria found in secretor-fed infants, we
probed the samples with bifidobacterial-specific quanti-
tative PCR (qPCR). The aggregated secretor-fed infant
samples were, on average, found to have significantly
higher absolute levels of bifidobacteria (109.0/g feces
versus 107.7/g feces, p < 0.001) (Figure 3). The distribu-
tion of the qPCR data was bimodal, with a large group
of samples with low levels of bifidobacteria (<107.6/g
feces, average 106.1) and a separate group with high
amounts of bifidobacteria (>108.9/g feces, average 1010.3),
with a striking lack of values falling in between the two
ranges (Figure 4). These two groupings of samples were
labeled ‘Low-BifqPCR’ and ‘High-BifqPCR’ samples, respectively.
Table 3 Maternal and infant clinical characteristics
Characteristic Secretor (n = 32) Non-secretor (n = 12)
Maternal age, years 31.1 ± 4.1 (24.0 to 45.0) 32.8 ± 3.5 (27.0 to 39.0)
Maternal BMI, pre-pregnancya, kg/m2 24.3 ± 4.7 (18.0 to 37.0)b 22.9 ± 3.9 (18.9 to 33.7)
Infant gestational age at birthc, week 39.7 ± 1.3 (37.0 to 42.1) 39.8 ± 1.2 (37.0 to 41.5)
Infant birth weightc, g 3,460 ± 399 (2,890 to 4,390) 3,530 ± 455 (2,660 to 4,370)
Infant birth lengthc, cm 51.6 ± 2.0 (47.0 to 57.2) 51.3 ± 1.8 (48.9 to 55.9)
Breast milk consumption post birthc, hours 3.1 ± 5.6 (0.3 to 24.0) 2.8 ± 5.8 (0.2 to 21.0)
Values, mean ± SD (range). aSelf-reported data for the time preceding pregnancy, n = 44. bn = 30. cSelf-reported, n = 44.
Bacteroides Clostridium Enterobacteriaceae
(Other) 
Escherichia/
Shigella
StreptococcusBifidobacterium
100%
75%
A
bu
nd
an
ce
Secretor 
Status
Lewis et al. Microbiome  (2015) 3:13 Page 4 of 21Much of the bifidobacterial abundance difference between
the two secretor status milk phenotypes appears to come
from variation in the time at which each infant transitions
from possessing a Low-BifqPCR’ gut community to posses-
sing a High-BifqPCR gut community. Bifidobacteria were
found to be established (High-BifqPCR) earlier in secretor-
fed infants (60% of infants versus 37.5% at day 6) and more
often (80% versus 50% by day 120) (Figure 5).
To examine the dependence of bifidobacterial abun-
dance in stool on secretor status phenotype in milk, a
contingency analysis was performed on the 105 available
matching milk and stool pairs (Figure 6). Of 35 milks
from non-secretors, 20 of the matched infant stool sam-
ples were Low-BifqPCR (57.1%). Of the 70 milks from se-
cretor women, 23 of the matched infant stool samples
were Low-BifqPCR (32.9%). A Pearson chi-square test was
significant (p = 0.0171), indicating that mother’s secretor
status and infant bifidobacteria levels are dependent var-
iables. A Fisher’s exact test yielded p = 0.015, suggesting
the probability that bifidobacteria levels will be High-
BifqPCR is greater for infants who are receiving milk from
secretor mothers.
We then tested whether differences in the types and
amounts of oligosaccharides present in the milk other0%
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Figure 1 Average fecal bacterial populations in the infant
cohort over time. Taken from order-level or higher classification
levels of the marker gene sequencing data.than 2′-fucosylation leads to differences in the amount of
bacteria present. Figure 7 shows that stool samples with
Low-BifqPCR counts (N = 43) and those with High-BifqPCR
counts (N = 62) were from infants that received matching
milk samples of mostly comparable glycan composition.
On average the milk received by Low-BifqPCR infants was
significantly higher in α(1-3/4)-fucosylated oligosaccharides
than milk received by the High-BifqPCR infants (14.2% ±
9.2% versus 10.1 ± 7.9%, respectively; p = 0.021), but this
may be mostly due to the trade-off between 2′- and 3′-
fucosylation related to secretor status, which was shown
above to correlate with an increase in bifidobacterialN S N S N S N S N S N S
25%
Ta
xa
 R
el
at
iv
e 50% N
S
0%
Figure 2 Comparison of relative levels of gut microbiota in
secretor-fed infants and non-secretor-fed infants. Asterisks
indicate significant differences (p < 0.05) in the relative levels of
various gut microbes using a Wilcoxon rank sum test. The color
boxplots show the quartiles above and below the median; the dark
line near the center of the box denotes the median. The whiskers
extend to the first and fourth quartiles, and the black dots show
outliers. N = non-secretor, S = secretor.
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Figure 3 Average absolute levels of bifidobacteria in secretor
versus non-secretor-fed infants (all samples of each secretor
status averaged together). The one-tailed type three t-test p value
was <0.001.
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Figure 5 Percentage of infants with high bifidobacteria over
time. Based on when each qualifying infant crossed the cutoff point
of 108.5 bifidobacterial genome equivalents/gram feces. Infants
qualified for this analysis by having the appropriate time points
available to know when they are first established with bifidobacteria;
for example, if the day 6 sample is missing, it is impossible to know
if the infant was established at that time or not, and thus, that infant
was excluded from this analysis.
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the High-BifqPCR group of infants received milk marginally,
but significantly higher in non-fucosylated neutral glycans
(1.5e08 ± 5.3e07 counts versus 1.2e08 ± 4.7e07 counts, p =
0.004) and α(1-2)-fucosylated glycans (9.1e07 ± 5.3e07
counts versus 6.8e07 ± 6.4e07 counts, p = 0.055 two-tailed
t-test, p = 0.028 one-tailed t-test).
Fecal glycoprofiles
To test whether bifidobacteria in general were a driver
of oligosaccharide consumption in the infant gut, we
measured types and amounts of oligosaccharides in the
feces as a proxy for (lack of ) consumption. Of 107 stoolHigh-BifqPCRLow-BifqPCR
Figure 4 Histogram of absolute bifidobacterial populations.
Bimodal distribution of results from bifidobacterial qPCR showing
the lack of intermediate levels.samples, glycans were detected in 103, of which bifido-
bacterial abundance was also measured in 102 samples.
Figure 8 shows a breakdown of how fecal glycoprofiles
differed between samples that were High-BifqPCR and
Low-BifqPCR. The absolute abundance of fecal glycans
(residual milk glycans present in infant stool) were sig-
nificantly higher in Low-BifqPCR stool samples (N = 42)
than in High-BifqPCR (N = 60). Significantly higher amounts
of non-fucosylated neutral (p < 0.0001), fucosylated
(p = 0.009), and sialylated species (p = 0.045) were left
behind in the Low-BifqPCR fecal samples, as determined
in ion counts per 100 μg of stool. The two groups showed
no significant differences in glycan composition in terms0.00
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Figure 6 Contingency plot of secretor status by bifidobacterial
content. Pearson chi-square test was significant (p = 0.0171), indicat-
ing that mother’s secretor status and infant bifidobacteria levels are
dependent variables. A Fisher’s exact test yielded p = 0.015.
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between the three glycan types.
Fecal bifidobacterial isolates
Noting the previous differences in fecal glycoprofiles, we
hypothesized that secretor mothers would enrich their
infants in bifidobacteria that are able to consume
2′-fucosylated HMOs. To test whether there were func-
tional differences in the ability of bifidobacteria from
infants with mothers of differing secretor statuses to con-
sume a secretor-type oligosaccharide (2′-fucosyllactose), we
obtained over 400 isolates from the 107 infant fecal samples
in this study for the purpose of growing them in vitro with
only 2′-fucosyllactose as a carbon source. Of these isolates,
382 were identified by the matrix-assisted laser desorption
ionization (MALDI) Biotyper (Bruker, Fremont, CA, USA)
as belonging to the genus Bifidobacterium. Bifidobacteria
were successfully isolated from 73 of the 107 samples.
Figure 9 shows a breakdown of these isolates by species
and mother’s secretor type over each of the four time
points. The most commonly isolated species were B. breve
and members of the B. longum group. As MALDI maynot reliably distinguish between members of this group,
we do not include subspecies designations in the descrip-
tion of the isolates. Notably, the B. longum group in-
creased in proportional representation over time in the
secretor-fed, but not in the non-secretor-fed infants. This
data may however be skewed by isolation bias. Of the
382 bifidobacteria isolates, 97 were chosen as a subset of
‘unique’ isolates to study further. The ‘unique’ subset
included only one isolate of each bifidobacterial species
obtained from each sample, selected at random from
among isolates of the same species. Multiple isolates of
the same species from the same fecal sample are likely
from a clonal population in the infant gut, thus our desig-
nation of these isolates as the ‘unique’ subset [37]. This
subsetting was necessary due to limitations in the amount
of 2′-fucosyllactose growth substrate available. Each
unique isolate was grown on 2′-fucosyllactose (2FL) to
test its ability to consume this prototypical secretor-type
sugar. Using the cutoff maximum optical densities (ODs)
shown in the example growth curves in Additional file 4:
Figure S2, we classified each isolate as a high, medium, or
low grower. Notably, a higher percentage of isolates from
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human milk oligosaccharide.
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from non-secretor-fed infants (Figure 10). In addition, of
the two isolates obtained from non-secretor-fed infants
that could grow on 2FL, one was a Bifidobacterium den-
tium strain, a species adapted to oral niches [38,39].
Fecal bifidobacterial (sub)species profiles
As different species and subspecies of bifidobacteria
have differences in their glycan consumption capabilities,
we investigated whether secretor- and non-secretor-fed
infants differed in their bifidobacterial content at a taxo-
nomic resolution higher than achievable by our marker
gene sequencing method (with current read lengths). At
first glance, it appeared as if there were no species-level
differences in the bifidobacterial populations of secretor-
fed and non-secretor-fed infants (Figure 11). However, a
difference was noted between secretor-fed infants and
non-secretor-fed infants in which bifidobacterial species
were present in high relative abundances when com-
pared to the microbiota as a whole. Specifically, there
was a difference in the correlation of the relative abundance
of various bifidobacterial species (from the bifidobacteria-
terminal restriction fragment length polymorphism (Bif-
TRFLP) data) with absolute (qPCR) and relative (amplicon
sequencing) bifidobacterial abundance (Figure 12, top and
bottom). Both the B. longum group and B. breve are posi-
tively correlated with bifidobacterial abundance in secretor-
fed infants, while only B. breve holds that distinction in
non-secretor-fed infants (B. bifidum is shown as correlated,
but is only present in one non-secretor-fed sample forwhich marker gene sequencing data is present, and at a
level of only 3% of total bifidobacteria). Interestingly, the
B. longum group is strongly anti-correlated with bifidobac-
terial abundance in non-secretor-fed infants. B. longum
subsp. infantis was not found in a single high-bifidobacteria
sample from non-secretor-fed infants (data not shown).
Phrased differently, distinct sets of bifidobacterial species
seem to be able to dominate the community in infants fed
by mothers of different secretor statuses.
To test whether the presence of different bifidobacterial
species led to differences in oligosaccharide content of the
feces (and thus putative oligosaccharide consumption), we
compared the fecal glycome between samples possessing
different dominant species of bifidobacteria (Figure 13).
Of the 60 stool samples with high-bifidobacterial abun-
dances, the species identified were Bifidobacterium ado-
lescentis (N = 4), B. bifidum (N = 1), B. breve (N = 20), B.
longum subsp. infantis (N = 7), B. longum subsp. longum
(N = 20), Bifidobacterium pseudocatenulatum (N = 7), and
the ambiguous B. pseudocatenulatum/bifidum designation
sometimes arising in the course of Bif-TRFLP analysis (N
= 1). Bifidobacterial species identified in stools with low
bifidobacteria abundance were B. bifidum (N = 1), B. breve
(N = 1), B. longum subsp. infantis (N = 1), B. longum subsp.
longum (N = 10), B. pseudocatenulatum (N = 22), and B.
pseudocatenulatum/bifidum (N = 1). In six samples, B.
longum subsp. infantis and B. longum subsp. longum were
of roughly equal abundance and, thus, were designated
more generally as ‘B. longum group’. Species groups with
N < 4 were omitted from statistical analysis. As expected,
glycan presence was not significantly different between
samples with different major bifidobacterial species in
Low-BifqPCR stool, as bifidobacteria were not likely the
major glycan consumer in samples where they were not
abundant (data not shown). In High-BifqPCR stool, there
were significant differences in the percentage of fucosy-
lated species (ANOVA p = 0.0001) and the percentage of
non-fucosylated neutral species (ANOVA p < 0.0001). By a
pairwise comparison, samples high in B. longum subsp.
infantis were shown to have a higher percentage of non-
fucosylated neutral oligosaccharides left behind in the
feces. Of the oligosaccharides not ostensibly consumed by
B. longum subsp. infantis, 52.3% ± 5.8% were non-
fucosylated neutral species on average. The relative abun-
dance of non-fucosylated neutral species was considerably
lower in samples high in all the other oligosaccharide
types, all with averages ≤30%. The percentage of fucosy-
lated oligosaccharides among the residual fecal glycans
was highest in infants with B. longum subsp. longum as
their dominant species of bifidobacteria, with an average
of 77.3% ± 3.7%. This value was significantly higher than
the fucosylated oligosaccharide percentages leftover in
samples dominated by B. breve (57.3% ± 3.7%, p = 0.003)
and B. longum subsp. infantis (42.7% ± 6.3%, p = 0.0001).
Figure 9 Bifidobacterial isolates obtained from fecal samples.
Data from 382 isolates from 38 babies across 73 samples. Eight species
of bifidobacteria were detected. The B. longum group and B. breve were
the most commonly detected. Other species detected include B.
pseudocatenulatum, B. catelanum, B. gallinarum, B. bifidum, B. dentium,
and B. angulatum. Non = non-secretor-fed, Sec = secretor-fed, and n =
number of samples from which isolates were obtained. The ‘n’ denotes
the number of samples represented in each bar, not the number
of isolates.
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Figure 11 Bifidobacterial species content: secretor versus non-
secretor. Based off of Bif-TRFLP (bifidobacteria-specific terminal re-
striction
fragment length polymorphism) and BLIR (Bifidobacterium longum/
infantis ratio) data. Some peaks in the electropherogram from Bif-
TRFLP could correspond to either B. bifidum or B. pseudocatenulatum
and are listed as such in their own category.
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As we had observed the impact of mother’s secretor sta-
tus on the amount and type of bifidobacteria in the in-
fant’s feces, we wished to investigate the impact of
secretor status on the rest of the infant’s gut community0%
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60%
70%
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Figure 10 Bifidobacterial isolates growth on 2′-fucosyllactose.
The OD achieved by each strain during growth on 2′-fucosyllactose
(2FL) was compared with the OD obtained in the absence of sugar
source as a negative control and lactose as a positive control. This
difference in OD (ΔOD) was used as a parameter to evaluate the
strain’s ability to grow on the 2FL.structures. We first classified infant gut communities in
a less-supervised manner, which would independently
capture important differences in community structures
while requiring fewer a priori choices on our part. Using
the QIIME 1.8.0 implementation of the BIO-ENV func-
tion of the ‘vegan’ R package (‘BEST’), a subset of the
most abundant bacterial species were tested for their
impact on community UniFrac distances [40]. Results
indicated that genera Bifidobacterium and Bacteroides
were the top two contributors to differences among the
given inputs (rho statistic = 0.586 when only those two
factors are considered, see Additional file 5: Table S3). A
principle coordinate analysis of the marker gene sequen-
cing results revealed three main clusters of samples,
(Additional file 6: Figure S3, middle plot) with one out-
lier. The three clusters were respectively distinguished
by high bifidobacterial content (BI), high Bacteroides
(BA), and high levels of a number of other taxa includ-
ing streptococci, enterobacteria, and clostridial species
(OT) (see Additional file 6: Figures S3, Additional file 7:
Figure S4, Additional file 8: Figure S5, Additional file 9:
Figure S6). The one outlier sample that fell into its own
category (high enterococci) was from a C-section infant
(Additional file 6: Figure S3). Infants often moved between
groups over time, and by day 120, few infants remained in
the OT group (Additional file 6: Figure S3). Notably, a
higher abundance of non-secretor-fed infants fell into the
OT area of the plot (Additional file 6: Figure S3). The infant
stools were thus divided into groups of Bacteroides (BAPCoA,
N= 24), bifidobacteria (BIPCoA, N= 38), or OTPCoA (N= 39)
dominated samples, based on the PCoA groupings de-
scribed previously. ANOSIM was used to test the
Figure 12 (See legend on next page.)
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(See figure on previous page.)
Figure 12 Pearson correlation matrices. Correlating the results of Bif-TRFLP (bifidobacteria-specific terminal restriction fragment length polymorphism),
qPCR, V4 16S amplicon sequencing, and BLIR (Bifidobacterium longum/infantis ratio) in non-secretor-fed (bottom) and secretor-fed (top) infants. The
number in each box is the Pearson correlation coefficient. The colored bar on the left side of the matrix indicates what type of data the row is.
Negative correlations are colored in shades of red and positive correlations are shown in shades of blue.
Lewis et al. Microbiome  (2015) 3:13 Page 10 of 21explanatory power of this grouping, with positive re-
sults (R statistic = 0.7887, p = 0.001 after 999 permuta-
tions, see Additional file 10: Table S4).
To investigate the impacts of having a microbiota
dominated by taxa other than bifidobacterial species,
we compared fecal glycomes across these three groups
using ANOVA (Figure 14). There were significant
differences in total oligosaccharide abundance (p =
0.0003) among the three groups, as well as differences
in the absolute and relative abundances of fucosylated
(p = 0.033 absolute, p = 0.027 relative) and non-
fucosylated neutral (p < 0.0001 absolute, p = 0.010 rela-
tive) oligosaccharide types. The OTPCoA group differed
the most from the BIPCoA and BAPCoA groups in terms
of absolute abundance of non-fucosylated neutral oli-
gosaccharides (Tukey-Kramer honestly significant dif-
ference (HSD) p < 0.0001 and p = 0.0002, respectively),
having significantly higher oligosaccharide amounts in
the stool, with an average of 1.51e08 ± 1.45e07 countsB
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Figure 13 Differences in the amount of fecal HMOs in infants
dominated by different species of bifidobacteria. Only samples
that were High-BifqPCR were included in this figure.in the OTPCoA group, versus 5.20e07 ± 1.47e07 counts
and 5.12e07 ± 1.90e07 counts in the BIPCoA and BAPCoA
groups, respectively. The relative abundance of non-
fucosylated neutral species differed most in the BAPCoA
group (accounting for 16.0% ± 3.9% of the total), being
significantly lower than those in the BIPCoA group (28.5%
± 3.0%, p = 0.035) and OTPCoA group (30.8% ± 2.9%,
p = 0.009). Additionally, the BAPCoA group also had a
higher percentage of fucosylated oligosaccharides than the
other two groups, with 71.3% ± 4.2% fucosylation, versus
57.9% ± 3.3% in the BIPCoA group (p = 0.035) and 58.44%
± 3.2% in the OTPCoA group (p = 0.044). The absolute
abundance of fucosylation in the OTPCoA group (2.57e08
± 2.52e07 ion counts) was significantly higher than that
of the BIPCoA group (1.64e08 ± 2.56e07 ion counts,
p = 0.029). Absolute and relative amounts of sialylation
were similar across all three groups.Fecal lactate
Bifidobacteria produce two main metabolic end prod-
ucts: lactate and acetate [41]. As a measure of metabolic
output from oligosaccharide consumption, we investi-
gated whether the concentration of lactate varied with
microbiota composition. Lactate was chosen due to its
lower volatility than acetate. Figure 15 shows a summary
of the differences in fecal lactate that correlate with
microbiota differences. The results are from a subset of
the samples, as only 87 samples had sufficient sample
quantity for the analysis (updated group sizes are in-
cluded with the tabulated result). Lactate concentration
did not appear to be normally distributed nor did the
Bartlett test indicate that most groupings were homosce-
dastic. Accordingly, log transformations were performed
prior to statistical analysis, and the results are tabulated
as the median in parts per thousand (ppt) by mass along
with the interquartile range.
When comparing groups based off of the bifidobacterial-
specific qPCR data (high/low), the High-BifqPCR group
was found to have higher levels of lactate (p = 0.0006). In
the groups based off of PCoA clustering (BAPCoA, BIPCoA,
OTPCoA), lactate was found to have significant differences
by ANOVA. Pairwise comparison of the lactate results
found no significant differences between BIPCoA and BAP-
CoA groups, but found that the OTPCoA group was lower
than both the BIPCoA group and the BAPCoA group with
p < 0.0001 in each case.
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Figure 14 Differences in the amount of fecal HMOs in infants of each PCoA group. Differences in the amount of each HMO class
remaining in the feces of samples that fell into each of the three main PCoA categories BAPCoA = Bacteroides, BIPCoA = Bifidobacterium,
OTPCoA = other taxa.
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While breastfeeding is overwhelmingly recommended as
the best source of nutrition for a newborn, it is clear that
not all breast milk is the same. Maternal diet, gestational
age of the infant, and lactation stages have been known
to influence the lipid and protein content of milk
[42,43]. Conversely, term milk glycan compositions ap-
pear relatively stable throughout lactation, perhaps
highlighting their importance to the developing infant
[44]. Decreasing milk glycan concentrations over the
course of lactation have been observed, for which the in-
creased volume consumed by infants at later stages of
nursing may compensate [45]. Milk glycan composition
from mothers who deliver prematurely was recently
shown to be more variable than mothers delivering term
infants [46]. Milk composition is also affected by the
mother’s glycosyltransferase genotype [47]. In this study,
the milk of secretors and non-secretors had modest dif-
ferences besides the amount of 2′-fucosylation. Secretors
had higher absolute amounts of sialylated sugars and
higher relative amounts of undecorated sugars. Non-
secretors had higher relative amounts of sialylated
sugars. These factors may also play a part in the shaping
of the secretor-fed infants’ microbiota. The potentially
confounding factor of the infant’s own glycosylationsystem, the timeline and levels of its expression, and its
potential influences on the microbiota were not explored
in this study and remain to be elucidated.
It is well established that differences in gut glycan
content affect the gut microbiota. Secretor status has
been shown to affect both the gut microbiota and me-
tabolite profiles in adults [48,49]. Secretor status also
specifically affects the species composition and abso-
lute abundance of gut bifidobacterial populations in
adults, with secretors having higher bifidobacterial abun-
dance [28,50]. Numerous studies have also associated in-
take of milk glycans with the initial colonization of the
infant gastrointestinal tract [34,51,52].
Our data provide insight into what types of milk in-
puts are most likely to lead to a high-bifidobacteria
microbiota in the context of our cohort (healthy infants
in a developed nation). The strongest corollaries of input
milk matched with a High-BifqPCR stool were high abso-
lute amounts of non-fucosylated neutral HMOs, high
absolute amounts of α(1-2)-fucosylated HMOs, and low
relative amounts of α(1-3/4)-fucosylated HMOs, perhaps
reflecting competitiveness with 2′-fucosylation. This
may be due to adaptations of infant-type bifidobacteria
to efficiently and selectively consume fucosylated and
undecorated oligosaccharides [11,12,52,53]. Our data
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glycans by different types of microbiota. BIPCoA feces
possessed fewer oligosaccharides of all types, suggesting
that these populations are capable of metabolizing
greater amounts of fucosylated, sialylated, and undecor-
ated sugars than communities low in bifidobacteria.
Some environmental pressures (pH, carbon source
availability, and so on) that select for bifidobacteria likely
select for other taxa as well. It is important to note that
relative abundances (such as provided by most marker
gene sequencing workflows) are a zero-sum game; when
one taxa’s relative abundance increases, it registers as a
concurrent decrease in other taxa. For some communi-
ties, this type of data may not adequately describe the
underlying ecological interactions. This is illustrated in
our study by the correlation difference between the rela-
tive and absolute bifidobacterial abundances with
Bacteroidales in secretor-fed infants (−0.3 with relative
abundance; 0.2 with absolute abundance). The relative
abundance data seem to indicate that Bacteroides is an-
tagonistic to (negatively correlated with) bifidobacteria,
while the absolute abundance (qPCR) data show that
they are mildly positively correlated with each other. It
may be that bifidobacteria and Bacteroides populations
respond to some environmental conditions in the same
way but not to the same magnitude. The presence of
HMGs that both genera can consume may be an ex-
ample of this [54]. Both genera were enriched in
secretor-fed infants, but the amplitude of the response
as shown by the correlation matrix, however, appears to
differ. This fact would be disguised by relative abun-
dance data alone.1
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Figure 15 Lactate concentrations by bifidobacteria qPCR group
or PCoA group. qPCR group (top) or PCoA group (bottom). The p
values are from a two-tailed Student’s t-test. BAPCoA = Bacteroides, BIP-
CoA = Bifidobacterium, OTPCoA = other taxa.Bifidobacteria and Bacteroides were implicated here
as the major HMO consumers in infants, which agrees
with previous in vitro work [55]. Bacteroides-dominated
communities had a lower percentage of undecorated
HMOs remaining, suggesting that they consume undec-
orated sugars preferentially to at least some decorated
sugars. Our data show that fucosylated sugars remain
at a significantly higher level (relative to other sugars)
by Bacteroides-dominated feces, implying that they are
not a preferred substrate of members of that taxa.
Bifidobacteria-dominated feces have lower absolute amounts
of fucosylated oligosaccharides than Bacteroides- and OT-
dominated communities. This suggests that fucosylated
oligosaccharides might enrich bifidobacteria more than
Bacteroides, supporting the difference shown in the cor-
relation matrix between absolute and relative abundance
of bifidobacteria and Bacteroides in secretor-fed infants.
However, it may be that only some bifidobacterial species
would possess this advantage, due to differences in abil-
ities of various species to consume fucosylated substrates.
In aggregate, the bifidobacterial species distribution
did not differ greatly between secretor-fed infants and
non-secretor-fed infants. As the species of bifidobacteria
present within an infant are dependent on environmen-
tal exposure, we tentatively conclude that this subset of
geographically co-located infants was exposed to similar
sets of bifidobacterial species. However, there was a large
difference in which species of bifidobacteria thrived in
each group of infants (defined as a species whose presence
tended to lead to domination of the microbiota by bifido-
bacteria). A broader range of bifidobacterial species were
positively correlated with the amounts of overall bifido-
bacteria within secretor-fed infants than non-secretor-fed
infants, suggesting that the presence of 2′-fucosylated
sugars allows a broader array of bifidobacterial species to
colonize the gut environment. According to our fecal iso-
late data, bifidobacteria that can grow on 2′-fucosylated
substrates are relatively uncommon, but represent a larger
proportion of total bifidobacteria in secretor-fed infants,
suggesting that this substrate is related to the competitive
fitness of these strains. Previous work supports the idea
that fucosidases are a differentiating factor in the ability to
grow on 2′-fucosylated sugars, although further study is
needed to definitively identify which class(es) of fucosi-
dase(s) is/are necessary [10].
That B. longum subsp. infantis thrives in secretor-fed in-
fants is no surprise. It possesses both classes of fucosidases
(GH95 and GH29) and was shown here to grow on
2′-fucosyllactose in vitro [10]. Feces dominated by this
subspecies also had lower percentages of fucosylated oli-
gosaccharides remaining. However, why B. longum subsp.
infantis failed to dominate in any non-secretor-fed infant
is somewhat perplexing. It may be that B. longum
subsp. infantis specializes in consuming 2′-fucosylated
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cies. B. breve on the other hand seems to be an oligosac-
charide generalist, as it was dominant in examples of
infants fed by both types of milk. B. breve strains are
known to be variable in their capacity to consume 2′-
fucosylated oligosaccharides [36].
The fact that B. breve and not B. longum subsp. infan-
tis seems to thrive in non-secretors may account for the
observation of Avershina et al. that B. breve abundance
separated the 10-day-old infants in their study into two
groups; one group where it accounted for <15%, whereas
in the other it accounted for >75% of the bifidobacterial
load. B. longum group members were dominant among
all infants in that study [56]. The B. breve-dominated
group may correspond to a non-secretor-fed infant mi-
nority in their study. As they did not track the secretor
status of the mothers in their study, this remains an
open question. It is also important to note that their
cohort was located in Norway and that the bacterial
exposure pattern may differ from that of our cohort.
The differing levels of competitiveness of B. breve and
B longum subsp. infantis in infants fed by mothers of
differing secretor status may also account for the obser-
vation that a three-probiotic mixture containing both
B. breve and B longum subsp. infantis was more effective
at promoting high levels of bifidobacteria in breastfed
premature infants than a probiotic containing B. breve
alone [57].
The bimodal distribution of bifidobacterial abundance
shown by qPCR is intriguing from an ecological perspec-
tive. A remarkably similar bimodal distribution with
comparable ranges was found by Mikami et al., suggest-
ing that this phenomena may be widespread [58]. Ac-
cording to this distribution, a useful cutoff value for
defining the population level of bifidobacteria in an in-
fant as high or low would be around 108/g of feces.
Using this cutoff, our data also agree with the growing
consensus that the establishment of bifidobacteria can
happen in many infants in the first week of life [59,60].
The ecological phenomena of alternative stable commu-
nity states may help explain this bimodal distribution in
the infant gut. Simply stated, alternative stable state theory
posits that a change in an ecosystem or in environmental
conditions can result in a drastic shift in the composition
of a community once some threshold or breakpoint is
reached (review of concept here [61]). Some bifidobacteria
are known to produce bacteriocins, which could contrib-
ute environmental pressure to maintaining alternate stable
community states, once a threshold number of bifidobac-
teria producing these bacteriocins is reached [62]. A more
likely mechanism by which these alternative stable states
might be formed in this environment involves the produc-
tion of lactate and short-chain fatty acids (SCFA) and their
influence on environmental pH. Perhaps once a certainthreshold of bifidobacteria/gram feces is reached the
amount of SCFA and lactate produced alters the pH of
the gut lumen, overcoming the buffering capacity of the
luminal contents. Due to the lower pH, a shift in the com-
munity structure could occur as non-acid-tolerant mem-
bers of the community die off. It is known that pH is a
major driver in the composition of soil microbial commu-
nities [63-66]. The same physiological constraints that se-
lect for microorganisms able to grow at a low pH in soil
likely apply in gut communities as well. One of these con-
straints may be effect of environmental pH on intracellu-
lar pH homeostasis and proton motive force [67].
Bacteroides in particular is known to be sensitive to low-
pH conditions, and the sensitivity is increased in the pres-
ence of SCFAs [68-71]. At least some enterobacteria are
known to be pH sensitive as well, which may indicate that
a low-pH gut is protective against infectious disease [70].
A decrease in the abundance of other microbes due to
pH changes, especially a decrease in competitors for
HMG substrates, such as Bacteroides [54,72], would allow
bifidobacteria to thrive from the reduced competition for
nutrients and space.
A survey of breastfed and formula-fed infants showed
that fecal pH and SCFAs were lower in breastfed infants
(pH mean 5.8) than formula-fed infants (pH mean 7.1),
but that lactic acid was higher, suggesting that lactic acid
might be a driver of pH [73]. Lactic acid has a lower
pKa than the common SCFAs and would be hypothe-
sized to have a greater effect on pH. B. longum subsp.
infantis grown on HMOs was found to produce higher
molar amounts of acetate and lactate [74]. Breastfed in-
fants are known to have higher levels of bifidobacteria
than formula-fed infants and also have different types of
bifidobacteria, which may be important to the SCFA
profile [75,76]. Both Bacteroides and bifidobacteria are
known to produce lactate, which may explain the differ-
ence we observed between the amount of lactate in feces
dominated by those groups as opposed to other species
[77]. Although our data showed that both bifidobacteria-
and Bacteroides-dominated fecal communities were
higher in lactic acid than communities dominated by
other species, our methods did not test the flux of lac-
tate production and utilization by both the microbiota
and the host. Nevertheless, lactate levels may be an in-
teresting biomarker of the composition of the microbial
community of the infant gut.
There are numerous ways in which the composition of
the gut microbiota impacts health. In the first 2 years of
life, the infant gut microbiome progresses through a series
of age-associated taxonomic changes. Infants and their
gut microbiota are sensitive to disruptions during the early
days and weeks of life [1,78,79]. Indeed, recent evidence
suggests infants suppress the immune system early in life
to aid in developing a healthy microbiota [80]. Like any
Lewis et al. Microbiome  (2015) 3:13 Page 14 of 21new ecosystem, the microbial community in the gut has
unfilled niches and has not developed mature levels of
colonization resistance [81]. The establishment of the gut
microbiota can impact an individual’s lifelong health, and
an early intervention that makes beneficial changes could
have lifelong positive effects [82,83].
Early establishment of bifidobacteria is thought to be
beneficial in numerous ways. Recently, domination by bifi-
dobacteria was shown to be associated with improved im-
mune response to vaccines [5]. Other benefits include
protection from pathogens and development of the neonatal
immune system [3,5,84,85]. For these reasons, our finding of
delayed bifidobacterial colonization of non-secretor-fed in-
fants (despite a higher incidence of exclusive breastfeeding
in non-secretors) has important implications. Understanding
the mechanism behind these differences will prove crucial
to potentially compensating for this problem, perhaps
through carefully chosen prebiotics and/or probiotics.
It may be that the deficit in bifidobacteria that non-
secretor-fed infants experience is due to the likelihood
of acquiring a species of bifidobacteria with metabolic
abilities appropriate for the type of milk being con-
sumed. As colonization by bifidobacteria is thought to
be dependent on stochastic exposure to environmental
strains, fewer appropriate potentially colonizing species
may mean a lower likelihood of obtaining an appropriate
one, whatever the mechanism of acquisition. As modern
hygiene standards and other cultural practices may lead
to a reduction in the exposure levels to different bifido-
bacterial species, the phenomenon of the low bifidobac-
teria infant might be an artefact of developed countries.
Indeed, recent studies of developing areas of the world
have revealed widespread domination of bifidobacteria
in infants [5,86,87]. More surveys of the absolute abun-
dance of infant bifidobacteria in developing and undevel-
oped areas of the world are needed, along with the
measurement of relevant exposure-related metadata.Conclusion
In conclusion, our work reveals important functional dif-
ferences in the microbiota of infants fed by mothers of dif-
fering secretor. This knowledge will be useful to those
selecting bifidobacterial species for probiotic interventions
in breastfed infants [88]. As a mother’s secretor status can
be determined relatively easily, it could be used as a marker
to target clinical interventions administering probiotics to
infants to match the set of glycans the mother provides.
This work provides context and insights for future hypoth-
esis testing related to the in vivo competition between bifi-
dobacteria and other members of the microbiota, as well
as among bifidobacterial species. Further work is necessary
to determine if these apparent differences in bifidobacterial
populations between secretor phenotypes are indeed adeveloped-world phenomenon, and if the ‘hygiene hypoth-
esis’ mechanism we propose here plays a role.
Methods
Subjects
Milk samples were obtained from 44 healthy women en-
rolled in the Foods for Health Institute Lactation Study
at UC Davis. Subjects were enrolled at approximately
34 weeks of gestation and asked to fill out detailed
health history questionnaires regarding demographics,
anthropometrics, pregnancy history, current and prior
health history, dietary habits and restrictions, physical
activity level, as well as medication and supplementation
intake history. Subjects reported the mode of delivery
of their infants (C-section versus vaginal), infant sex,
weight, length, and gestational age at birth, and filled out
questionnaires regarding the health of themselves and
their infants, as well as their diet throughout the study.
Subjects received lactation support and training on proper
sample collection from the study’s lactation consultant.
The UC Davis Institutional Review Board approved all as-
pects of the study, and informed consent was obtained
from all subjects. This trial was registered on clinical-
trials.gov (ClinicalTrials.gov Identifier: NCT01817127).
Breast milk samples
Subjects were instructed to write on all sample tubes the
time, date of collection, time of last meal prior to collec-
tion, and contents of the meals. Milk samples were col-
lected in the morning on day 6, 21, 71, and/or 120
postpartum using a modified published method [89] in-
volving milk collection by the subject from one breast
using a Harmony Manual Breastpump (Medela Inc.,
McHenry, IL, USA) 2 to 4 h after feeding her infant. Sub-
jects fully pumped one breast into a bottle, inverted six
times, transferred 12 ml into a 15-ml polypropylene tube,
and subsequently froze the sample in their kitchen freezers
(−20°C). Samples were picked up biweekly, transported to
the lab on dry ice, and stored at −80°C until processing.
Infant stool samples
Infant fecal samples were collected from the 44 breastfed-
term infants born to women in the study at 6, 21, 71,
and/or 120 days of life. Only one of the infants enrolled in
this study had received antibiotic treatment at 89 days
postpartum. All of the infants consumed breast milk, and
several infants also consumed infant formula or solid food
throughout the study duration. Parents were prompted to
fill out detailed labels on each stool sample vial regarding
infant intake of solids, infant formula, medications, and
supplements. Parents transferred their infant fecal samples
into sterile plastic tubes and were instructed to immedi-
ately store the samples in −20°C until transported by study
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tory on ice packs and stored at −80°C before processing.
Infant metadata statistics
Differences in demographics and characteristics be-
tween secretor and non-secretor women were ana-
lyzed by the Pearson chi-squared test. Differences in
clinical characteristics between secretor and non-
secretor women were analyzed non-parametrically for
unequal sample sizes using Mann-Whitney U test.
Alpha was set at 0.05.
Oligosaccharide extraction from milk and stool
Glycans were extracted from 50 μl of breast milk that
was aliquoted onto two 96-well plates. Milk was defatted
via centrifugation; the skimmed milk was collected
and subjected to an ethanol precipitation for the re-
moval of proteins. Following protein precipitation, the li-
quid fraction containing the oligosaccharides was dried
completely using centrifugal evaporation. The oligosac-
charides were reconstituted in 50 μl of water and re-
duced to their alditol forms with 1 M NaBH4. This is
done in order to eliminate alpha and beta anomers on
the reducing end of the sugars. Following reduction, the
oligosaccharide mixture was desalted and enriched by
solid-phase extraction on graphitized carbon-packed
96-well plates. Samples were desalted with six column
volumes (approximately 1.2 ml) of deionized water and
eluted with 20% acetonitrile in water, followed by 40%
acetonitrile and 0.01% trifluoroacetic acid in water. Eluent
was dried completely, reconstituted with 50 μl of deion-
ized water, and diluted 50 fold for liquid chromatography-
mass spectrometry (LC-MS) analysis.
Glycans were extracted from 50 mg of homogenized
stool. Stool was diluted to 100 mg/ml with deionized
water. Diluted stool samples were then homogenized by
rocking the vials overnight. The solid components of the
stool were then separated by centrifugation, then 100 μl
of the oligosaccharide-rich supernatant was aliquoted
onto two 96-well plates. Two times the sample volume
(approximately 300 μl) of ethanol was added to each
well. Proteins were precipitated at −80°C for 1.5 h, and
then centrifuged at 3,220 rcf for 30 min at 4°C. The
supernatant containing the HMOs was then collected
and dried completely. Samples were reconstituted in
100 μl of deionized water and reduced with 100 μl of
2 M NaBH4 (1 M final concentration in 200 μl solution
total). Reduction was performed in a 65°C water bath
for 1.5 h. Samples were immediately transferred to C8
packed 96-well plates for removal of residual proteins and
peptides by solid-phase extraction. The C8 flow-through
containing the oligosaccharides was then desalted and
enriched by solid-phase extraction on graphitized carbon
96-well plates. Samples were desalted and enrichedfollowing the same protocol for milk as described above.
Eluted glycans were then dried down, reconstituted in
100 μl of deionized water, and diluted tenfold for LC-MS
analysis.Glycoprofiling by nano-LC chip TOF (time of flight) mass
spectrometry
Both milk and fecal HMOs were analyzed using an Agilent
nano-LC Chip time-of-flight mass spectrometer (Agilent,
Santa Clara, CA, USA), as described previously [32,90].
Briefly, all chromatography was done on a nano-scale
microfluidic chip, equipped with a trapping column for
sample enrichment and an analytical column for separ-
ation, both packed with porous graphitized carbon (PGC).
Directly from the 96-well plate, 1 μl of HMO sample was
injected and loaded onto the enrichment column and sub-
sequently separated on the analytical column with a gradi-
ent optimized for glycan separation, using 3% acetonitrile
and 0.1% formic acid in water as aqueous solvent A and
90% acetonitrile and 0.1% formic acid in water as organic
solvent B (gradient also described previously). LC-MS data
was deconvoluted using Agilent’s MassHunter Qualitative
Analysis software, version B.03.01 (Agilent, Santa Clara,
CA, USA). Oligosaccharides were identified by matching
retention time and exact mass to a fully annotated, in-
house HMO library [90,91].Oligosaccharide quantitation and statistics
Total oligosaccharide abundance was determined for
each sample by summing the signal of all identified
HMO peaks (in ion counts). Oligosaccharides were then
grouped by glycan class, designated as either fucosylated,
sialylated, or non-fucosylated neutral (containing neither
fucose nor sialic acid residues). Total absolute amounts
of fucosylation and sialylation were determined by sum-
ming the abundance (peak volume in ion counts) of all
HMOs containing either fucose or sialic acid residues,
respectively. Relative amounts for each glycan class were
determined by normalizing absolute abundance of each
class to the total HMO signal and were expressed as
percentages. Two-tailed, unpaired t-test, with an α of
0.05, was used to compare glycan expression in milk
between secretor and non-secretor mothers, as well as
comparing milk and fecal HMOs received by infants
with low amounts of bifidobacteria versus those with
high amounts of bifidobacteria, as defined in the Bifido-
bacterium-specific qPCR section below. ANOVA was
used to compare fecal glycan expression between infants
whose dominant bacterial species were categorized as
Bacteroides, bifidobacteria, or ‘other’, by PCoA grouping
(explained below) followed by a pairwise comparison of
means between each of the aforementioned groups using
Tukey-Kramer HSD test, with an α of 0.05.
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To isolate bifidobacteria, 100 mg of each fecal sample
was aseptically transferred to a sterile tube, diluted ten-
fold with sterile phosphate buffered saline (PBS), and
homogenized by vortex. Serial dilutions were prepared
in PBS and inoculated on modified Bifidobacterium se-
lective iodoacetate mupirocin (BSIM) agar. Modified
BSIM agar was prepared by supplementing de Man
Rogosa Sharpe (MRS) media with 13 g/l agar, 500 mg/l
of L-cysteine-HCL, 20 mg/l of nalidixic acid, 50 mg/ml
mupirocin, 50 mg/ml kanamycin, 50 mg/ml polymixin B
sulfate, 100 mg/ml Iodoacetate, and 100 mg/ml 2,3,5-tri-
phenyltetrazolium chloride. The plates were inoculated
for 48 h at 37°C in an anaerobic chamber with an atmos-
phere containing approximately 5% carbon dioxide, 3%
hydrogen, and the remainder nitrogen. Up to ten result-
ing colonies from each sample with the appropriate col-
ony appearance were streaked onto BSIM plates for
purity for two passages. The resulting pure strains were
grown in MRS broth supplemented with 0.05% L-cyst-
eine and stored at −80°C in 50% glycerol.
MALDI-TOF Biotyper MS identification of isolates
Glycerol stocks of each isolate were streaked on MRS
plates and incubated at 37°C for 48 h in an anaerobic
chamber. A colony from each plate was added to 300 μl
nuclease-free water in a microcentrifuge tube and ho-
mogenized by vortex. Next, 900 μl of 98% ethanol was
added to the tube, pulse vortexed, and centrifuged for
2 min at maximum speed. The supernatant was removed
and the tubes were centrifuged again for 2 min. All li-
quid was removed from the pellets, and the samples
were left at room temperature to allow the ethanol to
evaporate. Subsequently, 25 μl of formic acid was then
added to each tube and homogenized by vortex, followed
by the addition of 25 μl of acetonitrile. Samples were
then centrifuged for 2 min, and 1 μl of extract was
placed on a MALDI target plate, left to dry at room
temperature, covered with an α-Cyano-4-hydroxycin-
namic acid (HCCA) matrix, and air dried. The MALDI
target plate was then analyzed by a MALDI Biotyper
(Bruker, Fremont, CA, USA), and the best database
match for each isolate was recorded.
Bacterial in vitro growth on 2′-fucosyllactose
Unique bifidobacterial isolates (one isolate of each identi-
fied species from each infant fecal sample) were tested for
growth on modified MRS (mMRS) with 3% filter-sterilized
2′-fucosyllactose as the sole carbon source, using mMRS
with 3% lactose as a sole carbon source as a positive con-
trol and a no-sugar mMRS as a negative control. mMRS
contains 10 g/l bacto-peptone, 5 g/l yeast extract, 2 g/l
dipotassium phosphate, 5 g/l sodium acetate, 2 g/l ammo-
nium citrate, 200 mg/l magnesium sulfate, 50 mg/lmanganese sulfate, 5 g/l beef extract, 500 mg/l cysteine-
HCL, and 1,000 g/l Tween 80. B. infantis ATCC 15697
and B. animalis UCD316 were included as positive and
negative growth controls, respectively. Isolates were
streaked from glycerol stock onto reinforced clostridial
media (RCM) plates and incubated at 37°C in an anaer-
obic chamber for 48 h. A resulting colony was inoculated
in 1 ml RCM broth at 37°C in an anaerobic chamber for
16 h. Five microliters of each resulting overnight culture
was used to inoculate 100 μl of mMRS medium supple-
mented with either 3% (w/v) of 2′-fucosyllactose, 3% (w/v)
of lactose, or mMRS without added sugar. The cultures
were grown in 96-well microtiter plates in triplicate and
covered with 20 μl of sterile mineral oil to avoid evapor-
ation. The incubations were carried out at 37°C in an an-
aerobic chamber. Cell growth was monitored by OD at
600 nm every 30 min preceded by 30 s of shaking at a
variable speed for a total of 96 h. The OD obtained for
each of the technical triplicates from each strain grown on
each substrate was averaged together and compared to the
OD obtained in the absence of sugar source. This differ-
ence in OD (ΔOD) was used as a parameter to evaluate
the strain’s ability to grow on the different substrates.
2′-fucosyllactose was produced as described previously [92].
Fecal DNA extraction
DNA was extracted from 150 mg of stool sample using
the ZR Fecal DNA MiniPrep kit (ZYMO, Irvine, CA,
USA) in accordance with the manufacturer’s instruc-
tions, which included a bead-beating step using a
FastPrep-24 Instrument (MP Biomedicals, Santa Ana,
CA, USA) for 2 min at 25°C at a speed of 6.5 m/s.
Breast milk and saliva DNA extraction
DNA was extracted from breast milk for the secretor
genotyping assay using the Qiagen DNeasy Blood and
Tissue kit (Qiagen, Venlo, Netherlands) with a modified
protocol for extracting DNA from animal saliva obtained
from the Qiagen website. Briefly, 2 ml of breast milk or
saliva was spun in a microcentrifuge at 15,000 rpm for
30 min to pellet human cells. Cells were washed once in
PBS and re-pelleted. The pellet was re-suspended in
180 μl of PBS and incubated with 25 μl of proteinase K
and 200 μl of buffer AL for 10 min at 56°C. Two hun-
dred microliters of ethanol was added to the sample and
mixed by vortexing. The entire sample was loaded onto
a spin column, and purification proceeded as per the
manufacturer’s recommended protocol from that point.
DNA was eluted in 30 μl of buffer EB for increased
concentration.
Determination of secretor genotype
Genomic DNA purified from each mother’s breast milk
or saliva was amplified with primers FUT2-F (5′-CC
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CTGCCTCTGGCTTAAAGA), which produces a 608-
bp amplicon. Each reaction contained 25 μl of 2X GoTaq
Green master mix (Promega, Madison, WI, USA), 5 μl of
DNA, 1 μl of each primer (10 μM), 6 μl of MgCl2
(25 mM), and 12 μl of nuclease-free water. Cycling condi-
tions were 95°C for 2 min followed by 35 cycles of 95°C
for 1 min, 60°C for 1 min, and 72°C for 1 min. A final
elongation was allowed at 73°C for 5 min, after which the
products were kept at 4°C overnight. Successful amplifica-
tion was confirmed by gel electrophoresis, and the PCR
products were purified using the QIAquick PCR purifica-
tion kit (Qiagen) according to the manufacturer’s instruc-
tions. Samples with low amplicon concentrations were
attempted again with 50 cycles of PCR, which was suc-
cessful in amplifying difficult samples. The amplicons
were then digested with BfaI, which cuts the DNA of indi-
viduals containing the mutated non-secretor rs601338
SNP (G→A, Trp→Ter) allele of the FUT2 gene, the pre-
dominant non-secretor mutation in the U.S. The resulting
digests were electrophoresed on a 2% agarose gel for ap-
proximately 2 h at 80 V, and the resulting bands were vi-
sualized using GelGreen dye (Biotum, Hayward, CA,
USA) under UV light. Individuals possessing a secretor al-
lele produce a 608-bp band on the gel after digestion,
while a non-secretor allele produces two bands with sizes
of 516 and 92 bp. In this way, it is possible to easily distin-
guish both homozygote genotypes from each other and
from heterozygotes.
Determination of secretor phenotype
The mother’s secretor status phenotype in milk was de-
termined by quantitating fucosylated glycan markers that
have been previously described and assessed for sensitiv-
ity and specificity [32]. Secretor status was determined
once per mother using milk from the earliest available
time point, as the influence of early milk is thought to
be most influential in establishing microbiota [6]. Thus,
by our definition, ‘secretor’ and ‘non-secretor’ might be
thought of as ‘early secretor’ or ‘early non-secretor’ since
the phenotypes were defined at an early time point. Among
these markers are α(1-2)-fucosylated structures, including
2′-fucosyllactose (2′FL, m/z 491.19), lactodifucotetraose
(LDFT, m/z 637.25), lacto-N-fucopentaose I (LNFP I,
mz/ 856.33), isomeric fucosylated lacto-N-hexaose (IFLNH
I, m/z 1221.45), difucosyllacto-N-hexaose a (DFLNH a, m/z
1367.51), and difucosyllacto-N-hexaose c (DFLNH c, m/z
1367.51). Cutoff values for the relative amounts of each
marker were used to distinguish secretor women from
non-secretor women, as described previously [32].
Bif-TRFLP
The method of Lewis et al. was used to perform the
Bifidobacterium-specific terminal restriction fragment lengthpolymorphism assay [93]. Briefly, DNA from feces was amp-
lified in triplicate by PCR using primers NBIF389 (5′-[HEX]-
GCCTTCGGGTTGTAAAC) and NBIF1018 REV (GAC-
CATGCACCACCTGTG). DNA was purified using the
Qiagen QIAquick PCR purification kit and then cut with
restriction enzymes AluI and HaeIII. The resulting frag-
ments were analyzed on an ABI 3100 genetic analyzer,
and sizes were compared against the published database
for species identification.
Bifidobacterium longum/infantis ratio (BLIR)
A PCR-based assay, BLIR, was developed in order to de-
termine which subspecies of B. longum were present
in each sample and to gain an estimate of their relative
abundance to each other. Three primers (FWD_
BL_BI (5-[HEX]-AAAACGTCCATCCATCACA), REV
_BL (5-ACGACCAGGTTCCACTTGAT), and REV_BI
(5-CGCCTCAGTTCTTTAATGT)) were designed to tar-
get a conserved portion of the genome (between Blon_0424
and Blon_0425) shared by both subspecies using multiple
genome sequences of each subspecies. FWD_BL_BI is com-
plementary to a sequence in both subspecies, while
REV_BL and REV_BI are complementary to nearby se-
quences in only B. longum subsp. longum and B. longum
subsp. infantis, respectively. FWD_BL_BI and REV_BL
amplify a fragment of the B. longum spp. longum genome
145 bp in length, while FWD_BL_BI and REV_BI amplify a
fragment of the B. longum subsp. infantis genome 114 bp
in length.
DNA from each sample was amplified by PCR using
0.5 μl of 10 μM stock of each of the above primers,
12.5 μl GoTaq Green Master Mix (Promega), 1 μl of
25 mM MgCl2, 1 μl of template DNA, and 9 μl of nucle-
ase free water. Cycling conditions were 95°C for 2 min,
30 cycles of 95°C for 1 min, 54°C for 1 min, and 72°C
for 30 seconds, followed by a 72°C extension for 5 min.
PCR products were purified from the mixture using the
QIAquick PCR purification kit (Qiagen), and diluted 1:10.
1.5 μl of the dilutions were analyzed by capillary electrophor-
esis on an ABI 3100 genetic analyzer (Applied Biosystems,
Carlsbad, CA, USA). The HEX fluorophore (Abcam,
Cambridge, UK) on the common primer allowed detec-
tion and differentiation of amplicon sizes and a rough
quantitation of the abundance of each amplicon based
on peak area when the samples were analyzed with
PeakScanner 2.0 software (Applied Biosystems, Carlsbad,
CA). A positive control was included with each PCR run
to ensure potential amplification of both B. longum subsp.
longum and B. longum subsp. infantis products.
Bifidobacterium qPCR
Levels of Bifidobacterium were measured by qPCR using
the methods of Penders et al. and performed on a 7500
Fast Real-Time PCR System (Applied Biosystems) [94].
Lewis et al. Microbiome  (2015) 3:13 Page 18 of 21All reactions were carried out in triplicate with a non-
template control and compared to a standard curve with
known quantities of bifidobacterial DNA.
Marker gene sequencing
DNA samples were prepared for 16S rRNA marker gene
sequencing as previously described [95] with the following
modifications. Universal barcoded primers with Illumina
sequencing adapters (Illumina, San Diego, CA, USA)
(adapters are italicized and the barcode is highlighted in
bold) V4F (5′-AATGATACGGCGACCACCGAGATCTAC
ACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNN
NNNGTGTGCCAGCMGCCGCGGTAA-3′) and V4Rev
(5′-CAAGCAGAAGACGGCATACGAGATCGGTCTCGG
CATTCCTGCTGAACCGCTCTTCCGATCTCCGGACTA
CHVGGGTWTCTAAT-3′) were used to PCR amplify the
V4 region of the 16S rRNA gene [95]. PCR reactions were
carried out in triplicate and contained 12.5 μl 2X GoTaq
Green Master Mix (Promega, Madison, WI, USA), 1.0 μl
25 mM MgCl2, 8.5 μl water, 0.5 μl forward and reverse
primers (10 μM final concentration), and 2.0 μl DNA. The
triplicate reactions were combined and cleaned, and
DNA concentrations were quantified using the PicoGreen
dsDNA kit (Thermo Fisher Scientific, Waltham, MA, USA).
An equimolar composite sample mixture was made, gel
purified, and sequenced at the University of California
DNA Technologies Core Facility on an Illumina MiSeq
sequencing platform (Illumina) (150 bp single read).
Sequence analysis
The QIIME software package (version 1.7.0) was used to
analyze the results of the Illumina sequencing run. Illu-
mina V4 16S rRNA gene sequences (Illumina) were
demultiplexed and quality filtered using the QIIME 1.7.0
software package with default settings unless otherwise
specified [96]. Reads were truncated after a maximum
number of three consecutive low quality scores. The
minimum number of consecutive high-quality base calls
to include a read (per single end read) as a fraction of
the input read length was 0.75. The minimum acceptable
Phred quality score was set at 20. Similar sequences
were clustered into operational taxonomic units (OTUs)
using open reference OTU picking with UCLUST soft-
ware [97]. Taxonomy was assigned to each OTU with
the Ribosomal Database Project (RDP) classifier [98] and
the RDP taxonomic nomenclature [99]. OTU representa-
tives were aligned against the Greengenes core set [100]
with PyNAST software [101]. PCoA plots were generated
using the default beta diversity analysis parameters.
Lactate concentrations
Lactate concentration was measured in a modified ver-
sion of the procedure developed by Ford et al. [102].
Shortly, lactate was extracted from solid feces byagitation in a 12-fold excess of pH 5.5 phosphate buffer
for 3 h at 4°C. Proteins were removed by ethanol precipi-
tation, and 100 μl of each extract was collected for ana-
lysis. After spiking the samples with stable isotope
standards, 0.2 M aqueous 3-Ethyl-1-[3-(dimethylamino)-
propyl]carbodiimide was used to link an excess of
2-phenyl-2-ethanamine to the fatty acids via a peptide bond.
The reaction was run for 20 min at room temperature and
quenched by an ice bath followed by immediate C18
solid-phase extraction. The extracted phenylethylamine
adducts were dried in a vacuum and reconstituted in
water.
The aqueous derivatives were analyzed on an Agilent
6490 QQQ LC/MS system (Agilent), and the response was
gauged by characteristic transitions due to the Y and B
fragmentation of the peptide bonds. Quantitation was
achieved by comparison of the derivatized analytes to in-
ternal stable isotope standards. Lactate was quantified by
comparison to 3,3,3-D3-lactate. During statistical analysis,
the Bartlett test was used to test for homoscedasticity, and
when needed, data was log transformed to meet the as-
sumptions required to conduct a parametric test. For pair-
wise comparisons, two-tailed Student’s t-tests were used.
Results were determined to be significant for p < 0.05.Additional files
Additional file 1: Table S1. Markers used for the determination of
secretor status. Raw ion counts and normalized sum of oligosaccharide
markers used to define secretor phenotype. Averages for each group are
included.
Additional file 2: Table S2. Breast milk and infant fecal sampling from
mother-infant dyads per time point. 1Self report by parent who was
prompted to answer the question ‘has your infant consumed any solids
or infant formula’ with each stool sample. The days of life listed include
each day when solids or infant formula intake was reported.
Additional file 3: Figure S1. C-section (N = 5) versus vaginal (N = 39)
birth over time. Shows composition of the microbiota as determined by
marker gene sequencing.
Additional file 4: Figure S2. Example growth curves of bifidobacterial
growth on 2′-fucosyllactose. One representative growth curve for each
level of OD (high ≥ 0.8, medium = 0.4 to 0.8, low ≤ 0.4) is shown here.
Data in Figure 13 shows the breakdown of all unique isolates by this
assignment method.
Additional file 5: Table S3. BIO-ENV analysis. Taxa used for evaluation
of importance to overall variation between microbial communities of
samples, along with iterative results adding in the next most important
group and respective Rho statistics for each iteration.
Additional file 6: Figure S3. PCoA plots of the NGS data. Colored by
days after birth (left), assigned group (center) and mother’s secretor
phenotype (right).
Additional file 7: Figure S4. PCoA plots of the NGS data. Colored by
the abundance of Bifidobacterium (left), Bifidobacteria from qPCR data
(center) and Bacteroides (right). Colors represent a spectrum of
abundance, with blue being high and red being low.
Additional file 8: Figure S5. PCoA plots of the NGS data. Colored by
the abundance of ‘Clostridiaceae_other’ (top left), Escherichia/Shigella (top
right), Veillonella (bottom left), and Streptococcus (bottom right). Colors
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being low.
Additional file 9: Figure S6. PCoA plots of the NGS data. Colored by
the abundance of ‘Enterobacteriaceae_other’ (top left), Streptococcus
(top right), Escherichia/Shigella (bottom left), and ‘Clostridiaceae_other’
(bottom right). Colors represent a spectrum of abundance, with blue
being high and red being low.
Additional file 10: Table S4. ANOSIM analysis. ANOSIM R statistics and
p values for various ways of grouping samples.
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